Xopus

Main Menu

  • Schemas
  • CSS
  • Chrome
  • Firefox
  • Fund

Xopus

Header Banner

Xopus

  • Schemas
  • CSS
  • Chrome
  • Firefox
  • Fund
Schemas
Home›Schemas›Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers

Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers

By Warren B. Obrien
March 2, 2022
0
0
  • Ostrem, JM, Peters, U., Sos, ML, Wells, JA & Shokat, KM K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503548–551 (2013).

    ADS CAS PubMed PubMed Central Google Scholar

  • Canon, J. et al. Clinical KRAS Inhibitor (G12C) AMG 510 stimulates anti-tumor immunity. Nature 575217-223 (2019).

    ADS CAS PubMed Google Scholar

  • Hallin, J. et al. The KRAS (G12C) inhibitor MRTX849 provides insight into the therapeutic sensitivity of KRAS mutant cancers in mouse models and patients. Discovery of cancer. ten54–71 (2020).

    CAS PubMed Google Scholar

  • Middleton, G. et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 583807–812 (2020).

    ADS CAS PubMed PubMed Central Google Scholar

  • Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23703–713 (2017).

    CAS PubMed PubMed Central Google Scholar

  • Ramalingam, SS et al. Overall survival with osimertinib in untreated advanced EGFR-mutated NSCLC. N.Engl. J.Med. 38241–50 (2020).

    CAS PubMed Google Scholar

  • Diederichs, S. et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol. Med. 8442–457 (2016).

    CAS PubMed PubMed Central Google Scholar

  • Group, PTC et al. Genomic basis of RNA alterations in cancer. Nature 578129-136 (2020).

    Google Scholar announcements

  • Consortium, APG AACR GENIE project: propelling precision medicine through an international consortium. Discovery of cancer. 7818–831 (2017).

    Google Scholar

  • Jane, PA et al. Selumetinib plus docetaxel versus docetaxel alone and progression-free survival in patients with kras-advanced mutant non-small cell lung cancer: the SELECT-1 randomized clinical trial. JAMA 3171844–1853 (2017).

    CAS PubMed PubMed Central Google Scholar

  • Kitai, H. et al. The epithelial-mesenchymal transition defines the feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in kras– mutant lung cancer. Discovery of cancer. 6754–769 (2016).

    CAS PubMed PubMed Central Google Scholar

  • Kruspig, B. et al. The ERBB network facilitates KRAS-induced lung tumorigenesis. Science. Transl. Med. teneaao2565 (2018).

    PubMed PubMed Central Google Scholar

  • Mol, HP et al. Afatinib limits K-RAS-induced lung tumorigenesis. Science. Transl. Med. teneaao2301 (2018).

    PubMed PubMed Central Google Scholar

  • LaMarche, MJ et al. Identification of TNO155, an allosteric inhibitor of SHP2 for the treatment of cancer. J.Med. Chem. 6313578–13594 (2020).

    CAS PubMed Google Scholar

  • Hong, DS et al. KRAS (G12C) inhibition with sotorasib in advanced solid tumors. N.Engl. J.Med. 3831207-1217 (2020).

    CAS PubMed PubMed Central Google Scholar

  • Hunter, JC et al. Biochemical and structural analysis of common KRAS mutations associated with cancer. Mol. Cancer Res. 131325-1335 (2015).

    CAS PubMed Google Scholar

  • Zhou, ZW et al. KRASQ61H signals preferentially via MAPK in an RAF dimer-dependent manner in non-small cell lung cancer. Cancer Res. 803719–3731 (2020).

    CAS PubMed Google Scholar

  • Oxnard, GR et al. Evaluation of resistance mechanisms and clinical implications in patients with EGFR T790M positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 41527-1534 (2018).

    Google Scholar PubMed

  • Ramalingam, SS et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann. Oncol 29VIII740 (2018).

    Google Scholar

  • Reinert, T. et al. Analysis of plasma cell-free DNA by ultra-deep sequencing in patients with stage I to III colorectal cancer. JAMA Oncol. 51124-1131 (2019).

    PubMed PubMed Central Google Scholar

  • Chabon, JJ et al. Integration of genomic features for the non-invasive early detection of lung cancer. Nature 580245-251 (2020).

    ADS CAS PubMed PubMed Central Google Scholar

  • Amendola, CR et al. KRAS4A directly regulates hexokinase 1. Nature 576482–486 (2019).

    CAS PubMed PubMed Central Google Scholar

  • Cartegni, L., Chew, SL & Krainer, AR Listening to Silence and Understanding Nonsense: Exon Mutations that Affect Splicing. Nat. Reverend Genet. 3285-298 (2002).

    CAS PubMed Google Scholar

  • Desmet, FO et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 37e67 (2009).

    MathSciNet PubMed PubMed Central Google Scholar

  • McVety, S., Li, L., Gordon, PH, Chong, G. & Foulkes, WD Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family . J.Med. Broom. 43153-156 (2006).

    CAS PubMed PubMed Central Google Scholar

  • Khvorova, A. & Watts, JK The chemical evolution of clinically useful oligonucleotide therapies. Nat. Biotechnol. 35238-248 (2017).

    CAS PubMed PubMed Central Google Scholar

  • Kim, J. et al. Personalized oligonucleotide therapy for a rare genetic disease. N.Engl. J.Med. 3811644-1652 (2019).

    CAS PubMed PubMed Central Google Scholar

  • Janes, MR et al. Targeting KRAS mutant cancers with a specific covalent G12C inhibitor. Cell 172578–589.e517 (2018).

    CAS PubMed Google Scholar

  • Brant, R. et al. Clinically viable gene expression assays with potential for predicting the benefits of MEK inhibitors. Clin. Cancer Res. 231471-1480 (2017).

    CAS PubMed Google Scholar

  • Chang, MT et al. The identification of recurrent mutations in cancer reveals great lineage diversity and mutational specificity. Nat. Biotechnol. 34155-163 (2016).

    CAS PubMed Google Scholar

  • Zammarchi, F. et al. Antitumorigenic potential of STAT3 alternative splicing modulation. proc. Natl Acad. Science. United States 10817779–17784 (2011).

    ADS CAS PubMed PubMed Central Google Scholar

  • Ross, SJ et al. Targeting krasdependent with AZD4785, a therapeutic high affinity antisense oligonucleotide inhibitor of kras. Science. Transl. Med. 9eaal5253 (2017).

    Google Scholar PubMed

  • Amodio, V. et al. Blocking EGFR restores KRAS resistanceG12C inhibition in colorectal cancer. Discovery of cancer. ten1129-1139 (2020).

    CAS PubMed PubMed Central Google Scholar

  • Klein, AF et al. Peptide-conjugated oligonucleotides evoke long-lasting correction of myotonic dystrophy in patient-derived cells and mice. J. Clin. Invest. 1294739–4744 (2019).

    CAS PubMed PubMed Central Google Scholar

  • Boisguerin, P. et al. Administration of therapeutic oligonucleotides with cell-penetrating peptides. Adv. Deliver. Tower. 8752–67 (2015).

    CAS PubMed PubMed Central Google Scholar

  • Imbert, M., Dias-Florencio, G. & Goyenvalle, A. Viral vector-mediated antisense therapy for genetic diseases. Genoa 851 (2017).

    PubMed Central Google Scholar

  • Sharma, Y. et al. A pan-cancer analysis of synonymous mutations. Nat. Common. ten2569 (2019).

    ADS PubMed PubMed Central Google Scholar

  • Cartegni, L., Wang, J., Zhu, Z., Zhang, MQ & Krainer, AR ESEfinder: A web resource for identifying exonic splicing activators. Nucleic Acids Res. 313568-3571 (2003).

    CAS PubMed PubMed Central Google Scholar

  • Smith, PJ et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exon splicing activators. Hmm. Mol. Broom. 152490-2508 (2006).

    CAS PubMed Google Scholar

  • Fairbrother, WG et al. RESCUE-ESE identifies candidate exon splicing activators in vertebrate exons. Nucleic Acids Res. 32W187–W190 (2004).

    CAS PubMed PubMed Central Google Scholar

  • Zhang, XH & Chasin, LA Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev. 181241–1250 (2004).

    CAS PubMed PubMed Central Google Scholar

  • Hori, S.-i et al. California2+ the enrichment in culture medium potentiates the effect of the oligonucleotides. Nucleic Acids Res. 43e128 (2015).

    PubMed PubMed Central Google Scholar

  • Garcia, EP et al. Validation of OncoPanel: a next-generation targeted sequencing assay for the detection of somatic variants in cancer. Camber. Pathol. Laboratory. Med. 141751–758 (2017).

    CAS PubMed Google Scholar

  • Odegaard, JI et al. Validation of a comprehensive plasma-based cancer genotyping test using orthogonal tissue and plasma-based methodologies. Clin. Cancer Res. 243539–3549 (2018).

    CAS PubMed Google Scholar

  • Related posts:

    1. Biden administration signals sweeping shift in focus to deal with cyber concerns in government procurement Baker Donelson
    2. My five # 436 | Inbound Marketing Agency
    3. Spring Boot Tutorial Brian Matthews
    4. ChaosSearch Data Platform Now Available in the AWS Marketplace
    Tagsunited states

    Recent Posts

    • Google Chrome adds virtual credit card numbers to protect your real ones – TechCrunch
    • How to take screenshots using the built-in screenshot tool in Mozilla Firefox on Windows 11 2022
    • Three Bard Faculty Pen Reviews for Artforum May 2022 Edition
    • 10 CSS background templates you can use on your website
    • Automotive Chromium Market Size and Overview 2022-2030 | Key Players – HELLA KGaA Hueck, Thule Group AB, Lund International, Covercraft Industries, Pep Boys – Manny

    Archives

    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021

    Categories

    • Chrome
    • CSS
    • Firefox
    • Fund
    • Schemas
    • Terms and Conditions
    • Privacy Policy